talampanel
Small moleculeexperimental
Talampanel is a drug which has been investigated for the treatment of epilepsy, malignant gliomas, and amyotrophic lateral sclerosis (ALS). — Wikipedia
Clinical trial activity
12 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2000 (NCT00004576)
Timeline
Indications
Mechanism of action
- Glutamate receptor-interacting protein 1ALLOSTERIC ANTAGONIST
GRIP1 allosteric antagonist
- Glutamate receptor ionotropic, AMPA 1ANTAGONIST
Glutamate receptor ionotropic, AMPA 1 antagonist
- Glutamate receptor ionotropic, AMPA 2ANTAGONIST
Glutamate receptor ionotropic, AMPA 2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3- Mol. weight
- 337.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTalampanel ↗
- ChEMBLCHEMBL61872 ↗
Also known as
- 1-(4'-aminophenyl)-3-acetyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5h-2,3-benzodiazepine
- 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7h-1,3-dioxolo(4,5-h)benzodiazepine
- gyki 53405
- gyki-53405
- gyki53773
- gyki 53773
- gyki-53773
- ly300164
- ly300164
- ly300164
- ly 300164
- ly-300164
- ly-300164
- ly-300164
- talampanel
- talampanel
- talampanel
- talampanel
- talampanel
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00964730 | Phase 1 | Oct 1, 2009 | PRACS, Teva |
| NCT00982150 | Phase 2 | Sep 1, 2009 | Teva |
| NCT00868361 | Phase 1 | May 1, 2009 | Covance, Teva |
| NCT00696332 | Phase 2 | Sep 1, 2008 | Teva |
| NCT00036296 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2006 | Teva |
| NCT00267592 | Phase 2 | Dec 1, 2005 | Teva |
| NCT00108667 | Phase 2 | Apr 1, 2005 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT00062504 | Phase 2 | Jul 1, 2003 | National Cancer Institute (NCI), Teva |
| NCT00064363 | Phase 2 | Jun 1, 2003 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00057460 | Phase 2 | Apr 1, 2003 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT00034814 | Phase 2 | Jan 1, 2002 | Teva |
| NCT00004576 | Phase 2 | Feb 1, 2000 | National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 8 | 8 | 2 | 2002 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 3 | 3 | 1 | 2000 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2003 |
| Covance | For profit | 1 | 0 | 1 | 2009 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2003 |
| PRACS | For profit | 1 | 0 | 1 | 2009 |
6 organizations
Page 1 / 1